CN109125623A - It is a kind of for treating the pharmaceutical composition of hepatopathy - Google Patents
It is a kind of for treating the pharmaceutical composition of hepatopathy Download PDFInfo
- Publication number
- CN109125623A CN109125623A CN201810063028.8A CN201810063028A CN109125623A CN 109125623 A CN109125623 A CN 109125623A CN 201810063028 A CN201810063028 A CN 201810063028A CN 109125623 A CN109125623 A CN 109125623A
- Authority
- CN
- China
- Prior art keywords
- parts
- hepatopathy
- treating
- pharmaceutical composition
- thick paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019423 liver disease Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 16
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 16
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 16
- 241000218231 Moraceae Species 0.000 claims abstract description 16
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 16
- 241000205407 Polygonum Species 0.000 claims abstract description 16
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 14
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 14
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 14
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 14
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 14
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 13
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 13
- 241000304432 Sedum sarmentosum Species 0.000 claims abstract description 13
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 29
- 235000019441 ethanol Nutrition 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 235000011132 calcium sulphate Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 239000001761 ethyl methyl cellulose Substances 0.000 claims description 3
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 241001598107 Imperata Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 6
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 238000000605 extraction Methods 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 210000005229 liver cell Anatomy 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000002398 materia medica Substances 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 239000002574 poison Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 20
- 238000011282 treatment Methods 0.000 description 16
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical group C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 13
- 208000010706 fatty liver disease Diseases 0.000 description 11
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- 235000020097 white wine Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 235000014101 wine Nutrition 0.000 description 5
- 240000006394 Sorghum bicolor Species 0.000 description 4
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000256856 Vespidae Species 0.000 description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- -1 Polyene Phosphatidylcholine class Chemical class 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of for treating the pharmaceutical composition of hepatopathy, the raw material including following parts by weight: 3~8 parts of cordyceps sinensis, 9~15 parts of Schisandra chinensis, 15~25 parts of Radix Glycyrrhizae, 10~16 parts of stringy stonecrop, 5~10 parts of fructus lycii, 20~30 parts of der Bockdorn, 5~10 parts of oriental wormwood, 6~12 parts of cassia seed, 9~15 parts of polygonum cuspidate, 3~6 parts of ganoderma lucidum, 20~30 parts of mulberries, 10~20 parts of rhizoma imperatae, 5~10 parts of flower of kudzuvine.Chinese materia medica preparation proposed by the present invention, accumulation of the fat in liver cell can be slowed down, reducing blood lipid, discharge liver poison, and have effects that activating microcirculation and removing stasis medicinal, nourishing the liver, protect liver, it is significantly reduced using rear alanine aminotransferase, Aspartate aminotransferase and blood lipid level, the intracorporal alcohol of people with fast decoupled and can be discharged, and liver cell regeneration speed is fast, and be formulated rationally, using safe, without side-effects, dosage is small, therapeutic effect is good, preparation method is simple, and raw material extraction efficiency is high.
Description
Technical field
The present invention relates to development of Chinese herb products technical fields more particularly to a kind of for treating the pharmaceutical composition of hepatopathy.
Background technique
Pressure is big in daily life people, improper diet, excessive drinking, stay up late for a long time etc. due to, cause more next
More people suffers from light or heavy hepatopathy, such as hepatitis B big and small three Yang, alcoholic liver disease, fatty liver, cirrhosis, liver tumour
Deng.Wherein alcoholic liver disease is a kind of hepatopathy often ignored by people, and Crack cause is mainly wine caused by patient's chronic alcoholism
Smart Poisoning liver diseases, the disease incidence in China large- and-medium size cities are on the rise.Clinically alcoholic liver disease is divided into 3
Type: fatty liver, hepatitis, cirrhosis, usually in morbidity, three is mixed.The conventional treatments of slight alcoholic liver disease
It is dietotherapy, abstinence from alcohol, can usually cures, but more serious alcoholic liver disease is just needed to take drugs to treat and prevent simultaneously
Send out the generation of disease.Drug currently used for treating alcoholic liver disease has Polyene Phosphatidylcholine class, milk thistle class, Radix Glycyrrhizae acid supplement
Deng.
Chinese medicine treats the long history of alcoholic liver disease, as an importance of modern hepatopathy complex treatment, in recent years
Increasingly to be paid close attention to by researcher.China Patent No.: CN 103830337 B of 103705731 B and CN discloses one kind and controls
Treat chronic alcoholic toxic liver disease Chinese medicine composition, and by pharmacodynamics investigate demonstrate the Chinese medicine composition can prevent or
Alcoholic fatty liver is treated, but the Chinese traditional medicine composition in two above publication is to high density lipoprotein level caused by alcoholic fatty liver
The elevating effect of white level is not significant, also not significant to the reducing effect of low-density lipoprotein white level；Based on above-mentioned existing skill
Deficiency present in art, the invention proposes a kind of for treating the pharmaceutical composition of hepatopathy.
Summary of the invention
That the purpose of the present invention is to solve therapeutic effects existing in the prior art is unobvious, dosage is big, treatment
The disadvantage of period length, and propose a kind of for treating the pharmaceutical composition of hepatopathy.
It is a kind of for treating the pharmaceutical composition of hepatopathy, the raw material including following parts by weight: 3~8 parts of cordyceps sinensis, the five tastes
9~15 parts of son, 15~25 parts of Radix Glycyrrhizae, 10~16 parts of stringy stonecrop, 5~10 parts of fructus lycii, 20~30 parts of der Bockdorn, oriental wormwood 5~10
Part, 6~12 parts of cassia seed, 9~15 parts of polygonum cuspidate, 3~6 parts of ganoderma lucidum, 20~30 parts of mulberries, 10~20 parts of rhizoma imperatae, flower of kudzuvine 5~10
Part.
Preferably, the Chinese medicine composition includes the raw material of following parts by weight: 5 parts of cordyceps sinensis, 12 parts of Schisandra chinensis, and Radix Glycyrrhizae
20 parts, 13 parts of stringy stonecrop, 8 parts of fructus lycii, 25 parts of der Bockdorn, 8 parts of oriental wormwood, 9 parts of cassia seed, 12 parts of polygonum cuspidate, 5 parts of ganoderma lucidum, mulberries
25 parts, 15 parts of rhizoma imperatae, 8 parts of flower of kudzuvine.
Preferably, the cassia seed, polygonum cuspidate and the mass ratio of ganoderma lucidum are 1~4:1.5~3:1.
Preferably, the mulberries, rhizoma imperatae and the mass ratio of flower of kudzuvine are 2~6:1~4:1.
Preferably, it is described for treating the preparation method of the pharmaceutical composition of hepatopathy the following steps are included:
S1, Schisandra chinensis, fructus lycii, cassia seed, polygonum cuspidate and ganoderma lucidum is taken to be placed in a reaction flask according to the proportion relation of each raw material,
It is first extracted with ethyl alcohol primary, then is extracted with water twice, is filtered after extracting every time, merging filtrate, when ethyl alcohol is recovered under reduced pressure to 60 DEG C
The thick paste A that relative density is 1.20~1.22；
S2, it is set according to proportion relation extracting liquorice, stringy stonecrop, der Bockdorn, oriental wormwood, mulberries, rhizoma imperatae and the flower of kudzuvine of each raw material
In reaction flask, the extracted by ether 1h first measured with 6~10 times, then the ethyl alcohol measured with 6~10 times extract 1h, finally with 6~10 times
The water of amount extracts 1h, filters after extracting every time, merging filtrate, when being concentrated under reduced pressure into 60 DEG C relative density be 1.22~1.24 it is thick
Cream B；
S3, it cordyceps sinensis is pulverized is placed in reaction flask, the water measured with 8 times extracts three times, filters after extracting every time, closes
And filtrate, the thick paste C that relative density is 1.18~1.22 when being concentrated into 60 DEG C；
S4, thick paste A, thick paste B and thick paste C are mixed, and auxiliary material are added, sterilize after mixing, then be made tablet,
Pill, granule or capsule are to get the pharmaceutical composition for treating hepatopathy.
Preferably, the additional amount of ethyl alcohol is 8 times for being extracted total quality of traditional chinese medicine, the additional amount of the water in the S1 step
For 10 times for being extracted total quality of traditional chinese medicine.
Preferably, the time that water extracts three times in the S3 step is respectively 2h, 1h and 0.5h.
Preferably, the auxiliary material be hydroxyethylmethylcellulose, it is hydroxypropyl methyl cellulose, ethylmethylcellulose, hard
Any several mixing in fatty acid magnesium, calcium sulfate, starch, lactose and water.
Chinese materia medica preparation proposed by the present invention is compounded by 13 taste Chinese medicines, including cordyceps sinensis, Schisandra chinensis, Radix Glycyrrhizae, hang down
Basin grass, fructus lycii, der Bockdorn, oriental wormwood, cassia seed, polygonum cuspidate, ganoderma lucidum, mulberries, rhizoma imperatae and flower of kudzuvine, the proportion of each raw material is reasonable,
Each Chinese medicine synergistic effect can slow down accumulation of the fat in liver cell, reducing blood lipid, discharge liver poison, and have activating microcirculation and removing stasis medicinal, support
The effect of liver, protect liver, after Chinese medicine composition proposed by the present invention, alanine aminotransferase, aspartic acid transamination
Enzyme, blood lipid level significantly reduce, and the intracorporal alcohol of people with fast decoupled and can be discharged, and liver cell regeneration speed is fast, and the drug
Composite formula rationally, using safe, without side-effects, dosage is small, good to the therapeutic effect of alcoholic liver disease, in addition to this, this
Invention also proposed a kind of easy to operate, and extraction efficiency is high, the side of the pharmaceutical composition of extraction time short preparation treatment hepatopathy
Method.
Specific embodiment
Combined with specific embodiments below the present invention is made further to explain.
Embodiment one
It is proposed by the present invention a kind of for treating the pharmaceutical composition of hepatopathy, the raw material including following parts by weight: worm summer in winter
5 parts of grass, 12 parts of Schisandra chinensis, 20 parts of Radix Glycyrrhizae, 13 parts of stringy stonecrop, 8 parts of fructus lycii, 25 parts of der Bockdorn, 8 parts of oriental wormwood, 9 parts of cassia seed,
12 parts of polygonum cuspidate, 5 parts of ganoderma lucidum, 25 parts of mulberries, 15 parts of rhizoma imperatae, 8 parts of flower of kudzuvine.
Preparation method includes the following steps:
S1, Schisandra chinensis, fructus lycii, cassia seed, polygonum cuspidate and ganoderma lucidum is taken to be placed in a reaction flask according to the proportion relation of each raw material,
The ethyl alcohol first measured with 8 times extracts once, then the water measured with 10 times extracts twice, filters after extracting every time, merging filtrate depressurizes back
The thick paste A that relative density is 1.20~1.22 when receiving ethyl alcohol to 60 DEG C；
S2, it is set according to proportion relation extracting liquorice, stringy stonecrop, der Bockdorn, oriental wormwood, mulberries, rhizoma imperatae and the flower of kudzuvine of each raw material
In reaction flask, the extracted by ether 1h first measured with 8 times, then the ethyl alcohol measured with 8 times extract 1h, and the water finally measured with 8 times extracts 1h,
It is filtered after extracting every time, merging filtrate, the thick paste B that relative density is 1.22~1.24 when being concentrated under reduced pressure into 60 DEG C；
S3, it cordyceps sinensis is pulverized is placed in reaction flask, the water measured with 8 times extracts three times, and extraction time is respectively
2h, 1h and 0.5h are filtered, merging filtrate after extracting every time, the thick paste C that relative density is 1.18~1.22 when being concentrated into 60 DEG C；
S4, thick paste A, thick paste B and thick paste C are mixed, and auxiliary material are added, sterilize after mixing, then be made tablet,
Pill, granule or capsule are to get the pharmaceutical composition for treating hepatopathy.
In the present invention, the auxiliary material is the mixed of hydroxyethylmethylcellulose, magnesium stearate, calcium sulfate, starch, lactose and water
It closes.
Embodiment two
It is proposed by the present invention a kind of for treating the pharmaceutical composition of hepatopathy, the raw material including following parts by weight: worm summer in winter
5 parts of grass, 10 parts of Schisandra chinensis, 20 parts of Radix Glycyrrhizae, 16 parts of stringy stonecrop, 8 parts of fructus lycii, 25 parts of der Bockdorn, 8 parts of oriental wormwood, 10 parts of cassia seed,
12 parts of polygonum cuspidate, 4 parts of ganoderma lucidum, 25 parts of mulberries, 15 parts of rhizoma imperatae, 8 parts of flower of kudzuvine.
Preparation method includes the following steps:
S1, Schisandra chinensis, fructus lycii, cassia seed, polygonum cuspidate and ganoderma lucidum is taken to be placed in a reaction flask according to the proportion relation of each raw material,
The ethyl alcohol first measured with 8 times extracts once, then the water measured with 10 times extracts twice, filters after extracting every time, merging filtrate depressurizes back
The thick paste A that relative density is 1.20~1.22 when receiving ethyl alcohol to 60 DEG C；
S2, it is set according to proportion relation extracting liquorice, stringy stonecrop, der Bockdorn, oriental wormwood, mulberries, rhizoma imperatae and the flower of kudzuvine of each raw material
In reaction flask, the extracted by ether 1h first measured with 10 times, then the ethyl alcohol measured with 10 times extract 1h, and the water finally measured with 10 times extracts
1h is filtered, merging filtrate after extracting every time, the thick paste B that relative density is 1.22~1.24 when being concentrated under reduced pressure into 60 DEG C；
S3, it cordyceps sinensis is pulverized is placed in reaction flask, the water measured with 8 times extracts three times, and extraction time is respectively
2h, 1h and 0.5h are filtered, merging filtrate after extracting every time, the thick paste C that relative density is 1.18~1.22 when being concentrated into 60 DEG C；
S4, thick paste A, thick paste B and thick paste C are mixed, and auxiliary material are added, sterilize after mixing, then be made tablet,
Pill, granule or capsule are to get the pharmaceutical composition for treating hepatopathy.
In the present invention, the auxiliary material is the mixed of hydroxypropyl methyl cellulose, magnesium stearate, calcium sulfate, starch, lactose and water
It closes.
Embodiment three
It is proposed by the present invention a kind of for treating the pharmaceutical composition of hepatopathy, the raw material including following parts by weight: worm summer in winter
8 parts of grass, 15 parts of Schisandra chinensis, 20 parts of Radix Glycyrrhizae, 16 parts of stringy stonecrop, 8 parts of fructus lycii, 30 parts of der Bockdorn, 6 parts of oriental wormwood, 6 parts of cassia seed,
12 parts of polygonum cuspidate, 3 parts of ganoderma lucidum, 25 parts of mulberries, 10 parts of rhizoma imperatae, 10 parts of flower of kudzuvine.
Preparation method includes the following steps:
S1, Schisandra chinensis, fructus lycii, cassia seed, polygonum cuspidate and ganoderma lucidum is taken to be placed in a reaction flask according to the proportion relation of each raw material,
The ethyl alcohol first measured with 8 times extracts once, then the water measured with 10 times extracts twice, filters after extracting every time, merging filtrate depressurizes back
The thick paste A that relative density is 1.20~1.22 when receiving ethyl alcohol to 60 DEG C；
S2, it is set according to proportion relation extracting liquorice, stringy stonecrop, der Bockdorn, oriental wormwood, mulberries, rhizoma imperatae and the flower of kudzuvine of each raw material
In reaction flask, the extracted by ether 1h first measured with 8 times, then the ethyl alcohol measured with 10 times extract 1h, and the water finally measured with 6 times extracts
1h is filtered, merging filtrate after extracting every time, the thick paste B that relative density is 1.22~1.24 when being concentrated under reduced pressure into 60 DEG C；
S3, it cordyceps sinensis is pulverized is placed in reaction flask, the water measured with 8 times extracts three times, and extraction time is respectively
2h, 1h and 0.5h are filtered, merging filtrate after extracting every time, the thick paste C that relative density is 1.18~1.22 when being concentrated into 60 DEG C；
S4, thick paste A, thick paste B and thick paste C are mixed, and auxiliary material are added, sterilize after mixing, then be made tablet,
Pill, granule or capsule are to get the pharmaceutical composition for treating hepatopathy.
In the present invention, the auxiliary material is the mixed of ethylmethylcellulose, magnesium stearate, calcium sulfate, starch, lactose and water
It closes.
Chinese medicine composition proposed by the present invention is as follows to the therapeutic effect experiment of hepatic injury caused by alcoholic liver disease:
1, material: cleaning grade SD rat, 60, male and female each 30,140~170g of weight；55 ° of strong, colourless liquor distilled from sorghum white wine；Powder-refining with water
Ji guest；Yellow Jackets；Alanine aminotransferase (ALT) kit, aspartate aminotransferase (AST) kit,
High-density lipoprotein cholesterol (HDL-C) kit, low density lipoprotein cholesterol (LDL-C) kit, triglycerides (TG)
Kit, cholesterol (TC) kit.
2, grouping, modeling and administration: randomly selecting 10 in 60 rats and be only used as blank rat, remaining 50 is only used as mould
Then type rat allows 50 rat models freely to drink 55 ° of strong, colourless liquor distilled from sorghum white wine and is configured to various concentration and the wine containing 10% white sugar
Water drinks, white wine degree are gradually incremented by according to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% (V/V), Mei Genong
Degree continues 10 days, and 40% when continues 20 weeks, 30 weeks total modeling time, constructs alcoholic fatty liver disease reason animal model, blank group
With model group rats equal ad lib full nutrition pellet during the experiment.After 30 weeks, model group rats are randomly divided into
Three groups of model control group, silibinin group, one group for the treatment of, two groups for the treatment of and treatment.
Gastric infusion continues surrounding, equal amount of distilled water is given once daily in blank control group and model control group once a day；
The each dosage of silibinin group is 25mg/kg weight；Treat one group of Chinese medicine composition for giving the preparation of embodiment one, each dosage
For 200mg/kg weight；Two groups of Chinese medicine compositions for giving the preparation of embodiment two are treated, each dosage is 200mg/kg weight；It controls
Three groups of Chinese medicine compositions for giving the preparation of embodiment three are treated, each dosage is 200mg/kg weight；12h after the last administration, fasting
It can't help water, with 3% yellow Jackets (20mg/kg) empty stomach injecting anesthetic, abdominal aortic blood detects each index.
3, experimental result
1) liver function index
| Group | ALT(U/L) | AST(U/L) |
| Blank control group | 31.12±5.11** | 43.21±6.25** |
| Model control group | 276.42±45.38 | 463.85±51.02 |
| Silibinin group | 191.21±19.62* | 312.58±36.54** |
| Treat one group | 45.25±8.65** | 58.25±8.24** |
| Treat two groups | 49.16±9.25* | 65.16±6.35** |
| Treat three groups | 51.21±6.28** | 72.33±4.25** |
Note: compared with model control group,*P < 0.05,**P<0.01。
Experimental result is shown, compared with blank control group, the ALT and AST of model control group rat are significantly increased, and illustrates wine
The success of essence fatty liver disease model；Compared with model control group, silibinin group, one group for the treatment of, two groups for the treatment of and treatment three
FBG, ALT, AST of the rat of group are significantly reduced, and ALT, AST reduce situation in three groups of one group for the treatment of, two groups for the treatment of and treatment
Be significantly better than silibinin group, show Chinese medicine composition proposed by the present invention can be significantly reduced alanine aminotransferase and
Aspartate aminotransferase is horizontal, has therapeutic effect to alcohol fatty liver.
2) blood lipids index
Note: compared with model control group,*P < 0.05,**P<0.01。
Experimental result is shown, compared with blank control group, the content of TG, TC and LDL-C of model control group rat are obvious
It increases, and the content of HDL-C is substantially reduced, and illustrates the success of alcohol fatty liver model；Compared with model control group, powder-refining with water
It Ji guest group, one group for the treatment of, two groups for the treatment of and treats three groups TG, TC and LDL-C of rat and decreases, the content of HDL-C has
It is increased, but the variation of silibinin group is unobvious, and treats one group, treats two groups and treat three groups of significant, tables that are changed significantly
Chinese medicine is reducing TG, TC and LDL-C content and is increasing in HDL-C content with excellent in bright Chinese medicine composition proposed by the present invention
Different synergistic effect, and effect is obvious.
The treatment of hepatic injury caused by how many pairs of alcohol fatty livers of Chinese medicine composition dosage proposed by the present invention is made
It is as follows with testing:
1, material: cleaning grade SD rat, 60, male and female each 30,140~170g of weight；55 ° of strong, colourless liquor distilled from sorghum white wine；Powder-refining with water
Ji guest；Yellow Jackets；Alanine aminotransferase (ALT) kit, aspartate aminotransferase (AST) kit,
High-density lipoprotein cholesterol (HDL-C) kit, low density lipoprotein cholesterol (LDL-C) kit, triglycerides (TG)
Kit, cholesterol (TC) kit.
2, grouping, modeling and administration: randomly selecting 10 in 60 rats and be only used as blank rat, remaining 50 is only used as mould
Then type rat allows 50 rat models freely to drink 55 ° of strong, colourless liquor distilled from sorghum white wine and is configured to various concentration and the wine containing 10% white sugar
Water drinks, white wine degree are gradually incremented by according to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% (V/V), Mei Genong
Degree continues 10 days, and 40% when continues 20 weeks, 30 weeks total modeling time, constructs alcoholic fatty liver disease reason animal model, blank group
With model group rats equal ad lib full nutrition pellet during the experiment.After 30 weeks, model group rats are randomly divided into
Model control group, silibinin group, low dose group, middle dose group and high dose group.
Gastric infusion continues surrounding, equal amount of distilled water is given once daily in blank control group and model control group once a day；
The each dosage of silibinin group is 25mg/kg weight；Low dose group gives the Chinese medicine composition of the preparation of embodiment one, each dosage
For 50mg/kg weight；Middle dose group gives the Chinese medicine composition of the preparation of embodiment one, and each dosage is 100mg/kg weight；It is high
Dosage group gives the Chinese medicine composition of the preparation of embodiment one, and each dosage is 200mg/kg weight；12h after the last administration, fasting
It can't help water, with 3% yellow Jackets (20mg/kg) empty stomach injecting anesthetic, abdominal aortic blood detects each index.
3, experimental result
1) liver function index
| Group | ALT(U/L) | AST(U/L) |
| Blank control group | 32.32±4.35** | 42.15±5.28** |
| Model control group | 281.25±35.32 | 461.57±49.25 |
| Silibinin group | 189.26±21.05* | 306.32±34.19** |
| Low dose group | 69.28±7.82** | 84.32±7.95* |
| Middle dose group | 57.25±7.56** | 76.18±6.30** |
| High dose group | 45.26±5.25** | 72.43±3.64** |
Note: compared with model control group,*P < 0.05,**P<0.01。
Experimental result is shown, compared with blank control group, the ALT and AST of model control group rat are significantly increased, and illustrates wine
The success of essence fatty liver disease model；Compared with model control group, silibinin group, low dose group, middle dose group and high dose
ALT, AST of the rat of group are significantly reduced, and ALT, AST reduction situation are aobvious in low dose group, middle dose group and high dose group
It writes and is better than silibinin group, show that alanine aminotransferase and Tianmen can be significantly reduced in Chinese medicine composition proposed by the present invention
Winter acid transaminases levels have therapeutic effect to alcohol fatty liver.
2) blood lipids index
Note: compared with model control group,*P < 0.05,**P<0.01。
Experimental result is shown, compared with blank control group, the content of TG, TC and LDL-C of model control group rat are obvious
It increases, and the content of HDL-C is substantially reduced, and illustrates the success of alcohol fatty liver model；Compared with model control group, powder-refining with water
TG, TC and LDL-C of the rat of Ji guest group, low dose group, middle dose group and high dose group decrease, and the content of HDL-C has
It is increased, but the variation of silibinin group is unobvious, and low dose group, middle dose group and high dose group are changed significantly significantly, and
It is more obvious than the variation of silibinin group, show that Chinese medicine is reducing TG, TC and LDL-C content in Chinese medicine composition proposed by the present invention
And the significant effect in raising HDL-C content, dosage are small.
The foregoing is only a preferred embodiment of the present invention, but scope of protection of the present invention is not limited thereto,
Anyone skilled in the art in the technical scope disclosed by the present invention, according to the technique and scheme of the present invention and its
Inventive concept is subject to equivalent substitution or change, should be covered by the protection scope of the present invention.
Claims (8)
1. a kind of for treating the pharmaceutical composition of hepatopathy, which is characterized in that the raw material including following parts by weight: cordyceps sinensis 3
~8 parts, 9~15 parts of Schisandra chinensis, 15~25 parts of Radix Glycyrrhizae, 10~16 parts of stringy stonecrop, 5~10 parts of fructus lycii, 20~30 parts of der Bockdorn,
5~10 parts of oriental wormwood, 6~12 parts of cassia seed, 9~15 parts of polygonum cuspidate, 3~6 parts of ganoderma lucidum, 20~30 parts of mulberries, 10~20 parts of rhizoma imperatae,
5~10 parts of flower of kudzuvine.
2. according to claim 1 a kind of for treating the pharmaceutical composition of hepatopathy, which is characterized in that the Chinese traditional medicine composition
Object includes the raw material of following parts by weight: 5 parts of cordyceps sinensis, 12 parts of Schisandra chinensis, and 20 parts of Radix Glycyrrhizae, 13 parts of stringy stonecrop, 8 parts of fructus lycii,
25 parts of der Bockdorn, 8 parts of oriental wormwood, 9 parts of cassia seed, 12 parts of polygonum cuspidate, 5 parts of ganoderma lucidum, 25 parts of mulberries, 15 parts of rhizoma imperatae, 8 parts of flower of kudzuvine.
3. according to claim 1 a kind of for treating the pharmaceutical composition of hepatopathy, which is characterized in that the cassia seed,
Polygonum cuspidate and the mass ratio of ganoderma lucidum are 1~4:1.5~3:1.
4. according to claim 1 a kind of for treating the pharmaceutical composition of hepatopathy, which is characterized in that the mulberries, white
Lalang grass rhizome and the mass ratio of flower of kudzuvine are 2~6:1~4:1.
5. according to claim 1 or 2 or 3 or 4 a kind of for treating the pharmaceutical composition of hepatopathy, which is characterized in that its
Preparation method the following steps are included:
S1, it takes Schisandra chinensis, fructus lycii, cassia seed, polygonum cuspidate and ganoderma lucidum to be placed in a reaction flask according to the proportion relation of each raw material, first uses
Ethyl alcohol extracts primary, then is extracted with water twice, filters after extracting every time, merging filtrate, opposite when ethyl alcohol is recovered under reduced pressure to 60 DEG C
The thick paste A that density is 1.20~1.22；
S2, it is placed in instead according to proportion relation extracting liquorice, stringy stonecrop, der Bockdorn, oriental wormwood, mulberries, rhizoma imperatae and the flower of kudzuvine of each raw material
It answers in bottle, the extracted by ether 1h first measured with 6~10 times, then the ethyl alcohol measured with 6~10 times extracts 1h, is finally measured with 6~10 times
Water extracts 1h, filters after extracting every time, merging filtrate, the thick paste B that relative density is 1.22~1.24 when being concentrated under reduced pressure into 60 DEG C；
S3, it cordyceps sinensis is pulverized is placed in reaction flask, the water measured with 8 times extracts three times, filters after extracting every time, merges filter
Liquid, the thick paste C that relative density is 1.18~1.22 when being concentrated into 60 DEG C；
S4, thick paste A, thick paste B and thick paste C are mixed, and auxiliary material is added, sterilized after mixing, then tablet, ball is made
Agent, granule or capsule are to get the pharmaceutical composition for treating hepatopathy.
6. according to claim 5 a kind of for treating the preparation method of the pharmaceutical composition of hepatopathy, which is characterized in that institute
The additional amount for stating ethyl alcohol in S1 step is 8 times for being extracted total quality of traditional chinese medicine, and the additional amount of the water is to be extracted the total matter of Chinese medicine
10 times of amount.
7. according to claim 5 a kind of for treating the preparation method of the pharmaceutical composition of hepatopathy, which is characterized in that institute
Stating the time that water extracts three times in S3 step is respectively 2h, 1h and 0.5h.
8. according to claim 5 a kind of for treating the preparation method of the pharmaceutical composition of hepatopathy, which is characterized in that institute
Stating auxiliary material is hydroxyethylmethylcellulose, hydroxypropyl methyl cellulose, ethylmethylcellulose, magnesium stearate, calcium sulfate, shallow lake
Any several mixing in powder, lactose and water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810063028.8A CN109125623A (en) | 2018-01-23 | 2018-01-23 | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810063028.8A CN109125623A (en) | 2018-01-23 | 2018-01-23 | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109125623A true CN109125623A (en) | 2019-01-04 |
Family
ID=64801613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810063028.8A Pending CN109125623A (en) | 2018-01-23 | 2018-01-23 | It is a kind of for treating the pharmaceutical composition of hepatopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109125623A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110664984A (en) * | 2019-11-18 | 2020-01-10 | 广东海洋大学 | Composition with effects of dispelling effects of alcohol and protecting liver and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766720A (en) * | 2010-01-22 | 2010-07-07 | 吴清军 | Medicine for treatment of liver disease |
| CN103301412A (en) * | 2013-07-07 | 2013-09-18 | 崔新明 | Traditional Chinese medicine composition for treating alcoholic liver |
| CN105287899A (en) * | 2015-11-20 | 2016-02-03 | 钱峰 | Traditional Chinese medicine alcoholism-relieving tea and production technology thereof |
-
2018
- 2018-01-23 CN CN201810063028.8A patent/CN109125623A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766720A (en) * | 2010-01-22 | 2010-07-07 | 吴清军 | Medicine for treatment of liver disease |
| CN103301412A (en) * | 2013-07-07 | 2013-09-18 | 崔新明 | Traditional Chinese medicine composition for treating alcoholic liver |
| CN105287899A (en) * | 2015-11-20 | 2016-02-03 | 钱峰 | Traditional Chinese medicine alcoholism-relieving tea and production technology thereof |
Non-Patent Citations (2)
| Title |
|---|
| 徐慧明等: "解酒护肝饮对酒精性肝病大鼠抗氧化损伤的实验研究", 《福建中医药》 * |
| 杨牧祥等: ""解酒护肝饮治疗酒精性肝病的临床疗效观察"", 《中国中医药信息杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110664984A (en) * | 2019-11-18 | 2020-01-10 | 广东海洋大学 | Composition with effects of dispelling effects of alcohol and protecting liver and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN102895432A (en) | Prescription and preparation method of rejoicing powder having new dosage form | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN105727205A (en) | Composition with weight losing and blood fat reducing functions and preparing method and application thereof | |
| CN105362384B (en) | A kind of Chinese medicine composition of Dealcoholic sobering-up and its application | |
| CN102846879B (en) | Composition for depressing blood fat | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN109125623A (en) | It is a kind of for treating the pharmaceutical composition of hepatopathy | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN1520831A (en) | Health-preserving liver-protecting drug and method for making same | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN110302352A (en) | A kind of olive granule and preparation method thereof | |
| CN102631479A (en) | Traditional Chinese medicine composition for improving damp heat constitution, preparation and preparation method thereof | |
| CN102462776A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method and application thereof | |
| CN102631486B (en) | Health care composition | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| CN106421132A (en) | Pollen pini composition with weight losing effect and preparation method thereof | |
| CN106474380A (en) | There is Chinese medicine composition, preparation of liver-protecting and alcoholism-relieving effect and preparation method thereof | |
| CN106581142A (en) | Compound traditional Chinese medicine composition capable of regulating blood fat and purpose thereof | |
| CN101164595A (en) | Traditional Chinese medicine for curing anorexia | |
| CN116474054A (en) | Traditional Chinese medicine composition for improving obesity and constipation as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190104 |
|
| RJ01 | Rejection of invention patent application after publication |